key: cord-0811873-pwy4xri6
authors: Rozencwajg, Sacha; Blet, Alice; Lamer, Antoine; Boisson, Matthieu; Clavier, Thomas; Abou-Arab, Osama
title: SARS-CoV-2 vaccination efficacy on hospitalisation and variants
date: 2021-04-23
journal: Anaesth Crit Care Pain Med
DOI: 10.1016/j.accpm.2021.100867
sha: 9ed08d9b25f8ec30d0bb59c46d493a2bb447e7cc
doc_id: 811873
cord_uid: pwy4xri6

nan

We then present a simplified table summarising data regarding the three main vaccines used in Europe, for which both laboratory and clinical data on the original "Wuhan" SARS-CoV-2 strain and the main variants of interests (i.e., "UK", "South African", and "Brazilian" variants) are available [1] [2] [3] [4] [5] [6] [7] [8] . These data should be interpreted with caution as new data are becoming available rapidly and in vitro testing may not be clinically validated in phase III clinical trials or real-life populations.

Confl i cts of i nte re st: The authors have no conflicts of interest to declare J o u r n a l P r e -p r o o f

COVID-19 vaccines: A race against time

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Immunity to SARS-CoV-2: Lessons Learned

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Infection-and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity